Production and use of fusion proteins comprising erythropoietin and immunoglobulin polypeptides. The erythropoietin fusion proteins have an increased in vivo half-like, as compared to wild type erythropoietin. The frequency with which it must be administered in patients in need thereof is reduced, compared to naturally-occurring erythropoietin.
申请公布号
WO9902709(A1)
申请公布日期
1999.01.21
申请号
WO1998US13930
申请日期
1998.07.06
申请人
BETH ISRAEL DEACONESS MEDICAL CENTER;SYTKOWSKI, ARTHUR, J.;STROM, TERRY, B.;ZHENG, XIN, XIAO